IP Library › Granted Patent US 8,093,396

Granted Patent B2

US 8,093,396 · App. 12/689,290 · Granted Jan 10, 2012

Benzthiazole inhibitors of poly(ADP-ribose)polymerase

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 8,093,396
App. No.: 12/689,290
Granted: Jan 10, 2012
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

Inhibitors of poly(ADP-ribose)polymerase having a structure of Formula (I), ways to make them and methods of treating patients using them are disclosed.

Claims (69)

1. A compound having a structure of Formula I

(I)

wherein

R 1 is selected from the group consisting of hydrogen, halogen and C 1 to C 3 alkyl;

R 2 is selected from the group consisting of hydrogen, halogen and C 1 to C 3 alkyl;

R 3 is selected from the group consisting of hydrogen, halogen and C 1 to C 3 alkyl;

R 4 is selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, and aryl wherein (a) the R 4 alkyl, alkenyl, alkynyl substituents are optionally substituted with one or more substituents selected from the group consisting of R 6 , halogen, cyano, oxo, —OR 10 , —C(O)R 10 , —C(O)OR 10 , —OC(O)R 10 , —NR 11 R 12 , —NR 11 C(O)R 12 , —NHC(O)NHR 11 , —C(O)NR 11 R 12 , —SR 10 , —S(O)R 10 , —SO 2 R 10 , —OC(O)OR 10 , —SO 2 NR 11 R 12 , —N 3 , —NO 2 , —CF 3 , —CF 2 CF 3 , —OCF 3 , and —OCF 2 CF 3 ; (b) wherein the R 4 cycloalkyl, cycloalkenyl, and aryl substituents are optionally substituted with one or more R 5 ;

R 5 is selected from the group consisting of R 6 , alkyl, alkenyl, alkynyl, halogen, cyano, oxo, —OR 13 , —C(O)R 13 , —C(O)OR 13 , —OC(O)R 13 , —NR 14 NR 15 , —NHC(O)NHR 14 , —C(O)NR 14 R 15 , —SR 13 , —S(O)R 13 , —OC(O)OR 13 , —SO 2 NR 14 R 15 , —N 3 , —NO 2 , —CF 3 , —CF 2 CF 3 , —OCF 3 , and —OCF 2 CF 3 wherein the R 5 alkyl, alkenyl, and alkynyl substituents are optionally substituted with one or more substituents selected from the group consisting of aryl, heterocyclyl, cycloalkyl, halogen, cyano, oxo, —OR 13 , —C(O)R 13 , —C(O)OR 13 , —OC(O)R 13 , —NR 14 R 15 , —NR 14 C(O)R 15 , —NHC(O)NHR 13 and —C(O)NR 14 R 15 ;

R 6 is aryl or heterocyclyl wherein the R 6 aryl and heterocyclyl substituents are optionally substituted with one or more substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, aminoalkyl, halogen, cyano, oxo, —OR 16 , —C(O)R 16 , —C(O)OR 16 , —OC(O)R 16 , —NR 17 R 18 , —NR 17 C(O)R 18 , —NHC(O)NHR 17 , —C(O)NR 17 R 18 , SR 16 , S(O)R 16 , SO 2 R 16 , OC(O)OR 16 , SO 2 NR 17 R 18 , —N 3 , —NO 2 , —CF 3 , —CF 2 CF 3 , —OCF 3 , and —OCF 2 CF 3 ;

R 10 , at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and cycloalkyl, wherein the alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and cycloalkyl are optionally substituted with one or more substituents independently selected from the group consisting of aryl, heterocyclyl, cycloalkyl, hydroxyl, halogen, cyano, and oxo;

R 11 and R 12 , at each occurrence, are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkenyl, and cycloalkyl, wherein the alkyl, alkenyl, alkynyl, heterocyclyl, and cycloalkyl are optionally substituted with one or more substituents independently selected from the group consisting of aryl, heterocyclyl, cycloalkyl, hydroxyl, halogen, cyano, and oxo;

R 13 , at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and cycloalkyl, wherein the alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and cycloalkyl are optionally substituted with one or more substituents independently selected from the group consisting of aryl, heterocyclyl, cycloalkyl, hydroxyl, halogen, cyano, and oxo;

R 14 and R 15 , at each occurrence, are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkenyl, and cycloalkyl, wherein the alkyl, alkenyl, alkynyl, heterocyclyl, and cycloalkyl are optionally substituted with one or more substituents independently selected from the group consisting of aryl, heterocyclyl, cycloalkyl, hydroxyl, halogen, cyano, and oxo;

R 16 , at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and cycloalkyl, wherein the alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and cycloalkyl are optionally substituted with one or more substituents independently selected from the group consisting of aryl, heterocyclyl, cycloalkyl, hydroxyl, halogen, cyano, and oxo; and

R 17 and R 18 , at each occurrence, are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkenyl, and cycloalkyl, wherein the alkyl, alkenyl, alkynyl, heterocyclyl, and cycloalkyl are optionally substituted with one or more substituents independently selected from the group consisting of aryl, heterocyclyl, cycloalkyl, hydroxyl, halogen, cyano, and oxo;

or a pharmaceutically acceptable salt thereof.

2. A compound having a structure of the Formula II

wherein:

R 4 is selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, and aryl wherein (a) the R 4 alkyl, alkenyl, and alkynyl substituents are optionally substituted with R 6 and further unsubstituted or substituted with one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, halogen, cyano, oxo, —OR 10 , —C(O)R 10 , —C(O)OR 10 , —OC(O)R 10 , —NR 11 R 12 , —NR 11 C(O)R 12 , —NHC(O)NHR 11 , —C(O)NR 11 R 12 , —SR 10 , —S(O)R 10 , —SO 2 R 10 , —OC(O)OR 10 , —SO 2 NR 11 R 12 , —N 3 , —NO 2 , —CF 3 , —CF 2 CF 3 , —OCF 3 , and —OCF 2 CF 3 (b) wherein the R 4 cycloalkyl, cycloalkenyl, and aryl substituents are optionally substituted with one or more R 5 ;

R 5 is selected from the group consisting of R 6 , alkyl, alkenyl, alkynyl, halogen, cyano, oxo, —OR 13 , —C(O)R 13 , —C(O)OR 13 , —OC(O)R 13 , —NR 14 NR 15 , —NHC(O)NHR 14 , —C(O)NR 14 R 15 , —SR 13 , —S(O)R 13 , —OS(O) 2 CF 3 , —SO 2 R 13 , —OC(O)OR 13 , —SO 2 NR 14 R 15 , —N 3 , —NO 2 , —CF 3 , —CF 2 CF 3 , —OCF 3 , and —OCF 2 CF 3 wherein the R 5 alkyl, alkenyl, and alkynyl substituents are optionally substituted with one or more substituents selected from the group consisting of aryl, heterocyclyl, cycloalkyl, halogen, cyano, oxo, —OR 13 , —C(O)R 13 , —C(O)OR 13 , —OC(O)R 13 , —NR 14 R 15 , —NR 14 C(O)R 15 , —NHC(O)NHR 13 and —C(O)NR 14 R 15 ;

or a pharmaceutically acceptable salt thereof.

3. The compound of claim 2 wherein R 4 is selected from the group consisting of alkyl, cycloalkyl, cycloalkenyl, and aryl; or a pharmaceutically acceptable salt thereof.

4. The compound of claim 2 , wherein R 4 is phenyl.

5. The compound of claim 4 wherein R 4 is optionally substituted with one to three R 5 , wherein R 5 is selected from the group consisting of R 6 , unsubstituted alkyl, and —OS(O) 2 CF 3 , wherein R 6 is unsubstituted phenyl or an unsubstituted heterocyclyl selected from the group consisting of

or a pharmaceutically acceptable salt thereof.

6. A compound having a structure of the Formula III

wherein R 20 , R 21 , R 22 , R 23 and R 24 are independently selected from the group consisting of hydrogen, R 6 , alkyl, alkenyl, alkynyl, halogen, cyano, oxo, —OR 13 , —C(O)R 13 , —C(O)OR 13 , —OC(O)R 13 , —NR 14 R 15 , —NR 14 C(O)R 15 , —NHC(O)NHR 14 , —C(O)NR 14 R 15 , —SR 13 , —S(O)R 13 , —OS(O) 2 CF 3 , —SO 2 R 13 , —OC(O)OR 13 , —SO 2 NR 14 R 15 , —N 3 , —NO 2 , —CF 3 , —CF 2 CF 3 , —OCF 3 , and —OCF 2 CF 3 ;

or a pharmaceutically acceptable salt thereof.

7. The compound of claim 6 wherein at least 2 of R 20 , R 21 , R 23 and R 24 are hydrogen, and R 22 is selected from the group consisting of R 6 , alkyl, —OR 13 , —C(O)R 13 , —C(O)OR 13 , —OC(O)R 13 , —NR 14 R 15 , —NR 14 C(O)R 15 , —NHC(O)NHR 14 , —C(O)NR 14 R 15 , —SR 13 , —S(O)R 13 , —OS(O) 2 CF 3 , —SO 2 R 13 , —OC(O)OR 13 , —SO 2 NR 14 R 15 , —N 3 , —NO 2 , —CF 3 , —CF 2 CF 3 , —OCF 3 , and —OCF 2 CF 3

R 6 is phenyl or 5, 6 or 7-membered heterocyclyl, wherein the R 6 phenyl and heterocyclyl substituents are optionally substituted with one or more substituents independently selected from the group consisting of alkyl, alkenyl, aminoalkyl, halogen, oxo, —OR 16 , —C(O)R 16 , —C(O)OR 16 , —NR 17 R 18 , —NR 17 C(O)R 18 , —C(O)NR 17 R 18 , SR 16 , S(O)R 16 , SO 2 R 16 , SO 2 NR 17 R 18 , —CF 3 , and OCF 3 ;

or a pharmaceutically acceptable salt thereof.

8. The compound of claim 6 wherein

R 20 , R 21 , R 23 and R 24 are hydrogen, and R 22 is selected from the group consisting of R 6 , alkyl, alkenyl, halogen, cyano, oxo, —OR 13 , —C(O)R 13 , —C(O)OR 13 , —OC(O)R 13 , —NR 14 R 15 , —NR 14 C(O)R 15 , —NHC(O)NHR 14 , —C(O)NR 14 R 15 , —SR 13 , —S(O)R 13 , —OS(O) 2 CF 3 , —SO 2 R 13 , —OC(O)OR 13 , —SO 2 NR 14 R 15 , —N 3 , —NO 2 , —CF 3 , —CF 2 CF 3 , —OCF 3 , and —OCF 2 CF 3 wherein the R 22 alkyl, alkenyl, and alkynyl substituents are optionally substituted with one or more substituents selected from the group consisting of aryl, heterocyclyl, cycloalkyl, halogen, cyano, oxo, —OR 13 , —C(O)R 13 , —C(O)OR 13 , —OC(O)R 13 , —NR 14 R 15 , —NR 14 C(O)R 15 , —NHC(O)NHR 13 and —C(O)NR 14 R 15 ;

R 6 is aryl or 3, 4, 5, 6, 7 or 8 membered ring heterocyclyl wherein the R 6 aryl and heterocyclyl substituents are optionally substituted with one or more substituents independently selected from the group consisting of alkyl, alkenyl, halogen, cyano, oxo, —OR 16 , —C(O)R 16 , —C(O)OR 16 , —OC(O)R 16 , —NR 17 R 18 , —NR 17 C(O)R 18 , —C(O)NR 17 R 18 , SR 16 , S(O)R 16 , SO 2 R 16 , SO 2 NR 17 R 18 , —CF 3 , —CF 2 CF 3 , and —OCF 3 ;

R 10 , at each occurrence, is independently selected from the group consisting of hydrogen and alkyl;

R 11 and R 12 , at each occurrence, are independently selected from the group consisting of hydrogen and alkyl;

R 13 , at each occurrence, is independently selected from the group consisting of hydrogen and alkyl;

R 14 and R 15 , at each occurrence, are independently selected from the group consisting of hydrogen and alkyl;

R 16 , at each occurrence, is independently selected from the group consisting of hydrogen and alkyl; and

R 17 and R 18 , at each occurrence, are independently selected from the group consisting of hydrogen and alkyl;

or a pharmaceutically acceptable salt thereof.

9. The compound of claim 6 wherein

R 22 is selected from the group consisting of R 6 , alkyl, —OR 13 , and —OS(O) 2 CF 3 ;

R 6 is unsubstituted phenyl or an unsubstituted heterocyclyl selected from the group consisting of

and wherein R 13 is selected from the group consisting of hydrogen and alkyl;

or a pharmaceutically acceptable salt thereof.

10. A compound selected from the group consisting of

4-[4-(aminocarbonyl)-1,3-benzothiazol-2-yl]phenyl trifluoromethanesulfonate;

2-(1,1′-biphenyl-4-yl)-1,3-benzothiazole-4-carboxamide;

2-(4-pyridin-3-ylphenyl)-1,3-benzothiazole-4-carboxamide; and

2-(4-pyridin-4-ylphenyl)-1,3-benzothiazole-4-carboxamide;

or a pharmaceutically acceptable salt thereof.

11. A pharmaceutical composition comprising a compound or pharmaceutically acceptable salt of claim 1 and pharmaceutically acceptable excipient.

Assignments (2)

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 17, 2013

From: ABBOTT LABORATORIES

To: ABBVIE INC.

Reel/Frame 030237/0597 →

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 17, 2010

From: PRZYTULINSKA, MAGDALENA K.; PENNING, THOMAS D.; TONG, YUNSONG

To: ABBOTT LABORATORIES

Reel/Frame 023947/0862 →